Antoine Awad - 10 Nov 2023 Form 4 Insider Report for SYNLOGIC, INC. (SYBX)

Reporting relationship
Chief Operating Officer
Issuer ticker
SYBX
Reported as of
10 Nov 2023
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
14 Nov 2023, 19:22:51 UTC
Prior SEC filing
05 Apr 2023
Next SEC filing
04 Apr 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Antoine Awad

Key filing fact

Antoine Awad filed Form 4 for SYNLOGIC, INC. (SYBX) on 14 Nov 2023.

Key facts

  • This page summarizes Antoine Awad's Form 4 filing for SYNLOGIC, INC. (SYBX).
  • 16 reported transactions and 16 derivative rows are listed below.
  • Accepted by SEC: 14 Nov 2023, 19:22.

Change

  • Previous filing in this sequence was filed on 05 Apr 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SYBX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-3,666
Change %
-100%
Price
Shares after
0
Date
10 Nov 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,666
Exercise price
$130.35
Footnotes
F1, F2
SYBX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-666
Change %
-100%
Price
Shares after
0
Date
10 Nov 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
666
Exercise price
$128.85
Footnotes
F1, F2
SYBX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-6,666
Change %
-100%
Price
Shares after
0
Date
10 Nov 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
6,666
Exercise price
$9.30
Footnotes
F1, F3
SYBX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-4,666
Change %
-100%
Price
Shares after
0
Date
10 Nov 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,666
Exercise price
$25.50
Footnotes
F1, F4
SYBX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-4,666
Change %
-100%
Price
Shares after
0
Date
10 Nov 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,666
Exercise price
$27.75
Footnotes
F1, F5
SYBX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-4,666
Change %
-100%
Price
Shares after
0
Date
10 Nov 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,666
Exercise price
$52.50
Footnotes
F1, F6
SYBX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-11,031
Change %
-100%
Price
Shares after
0
Date
10 Nov 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
11,031
Exercise price
$29.25
Footnotes
F1, F7
SYBX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-16,666
Change %
-100%
Price
Shares after
0
Date
10 Nov 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
16,666
Exercise price
$9.30
Footnotes
F1, F8
SYBX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+3,666
Change %
Price
Shares after
3,666
Date
10 Nov 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,666
Exercise price
$1.85
Footnotes
F1, F2
SYBX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+666
Change %
Price
Shares after
666
Date
10 Nov 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
666
Exercise price
$1.85
Footnotes
F1, F2
SYBX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+6,666
Change %
Price
Shares after
6,666
Date
10 Nov 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
6,666
Exercise price
$1.85
Footnotes
F1, F3
SYBX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+4,666
Change %
Price
Shares after
4,666
Date
10 Nov 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,666
Exercise price
$1.85
Footnotes
F1, F4
SYBX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+4,666
Change %
Price
Shares after
4,666
Date
10 Nov 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,666
Exercise price
$1.85
Footnotes
F1, F5
SYBX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+4,666
Change %
Price
Shares after
4,666
Date
10 Nov 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,666
Exercise price
$1.85
Footnotes
F1, F6
SYBX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+11,031
Change %
Price
Shares after
11,031
Date
10 Nov 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
11,031
Exercise price
$1.85
Footnotes
F1, F7
SYBX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+16,666
Change %
Price
Shares after
16,666
Date
10 Nov 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
16,666
Exercise price
$1.85
Footnotes
F1, F8
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 8 footnotes

Footnote F1

In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.

Footnote F2

The shares subject to this option are fully vested as of the date hereof.

Footnote F3

These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met.

Footnote F4

The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2020 through April 1, 2024.

Footnote F5

The shares subject to this option vest in approximately equal monthly installments beginning on July 1, 2020 through July 1, 2024.

Footnote F6

The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2021 through April 1, 2025.

Footnote F7

The shares subject to this option vest in approximately equal monthly installments beginning on February 4, 2022 through February 4, 2026.

Footnote F8

The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .